Tunlametinib

妥拉美替尼

Report date: 2026/04/16 20:00:17
NME

Base Information

Drug NameTunlametinib
Drug Alias Name妥拉美替尼科露平HL-085HL085
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDual specificity mitogen-activated protein kinase kinase 1 inhibitorsDual specificity mitogen-activated protein kinase kinase 2 inhibitors
TargetsDual specificity mitogen-activated protein kinase kinase 1Dual specificity mitogen-activated protein kinase kinase 2
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungThyroid Neoplasms +[8] 
Global Approved IndicationsMelanoma
Approved Indications in ChinaMelanoma
Original Approved Country/TerritoryMainland China
Original Approved Date2024/03/12
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesShanghai Kezhou Pharmaceutical Co., Ltd.
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesShanghai Kezhou Pharmaceutical Co., Ltd.Fudan UniversityTianjin Medical University Second Hospital +[5] 
Inactive CompaniesN/A
Active IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungThyroid Neoplasms +[8] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A